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Abstract
Fatty acids are key components in the structural diversity of lipids and play a strategic role in the functional properties of lipids which 
determine the structural and functional integrity of neural cell membranes, the generation of lipid signaling mediators, and the chemical 
reactivity of acyl chains. The present study analyzes the profile of lipid fatty acid composition of membranes of human frontal cortex area 8 
in individuals ranging from 40 to 90 years old. Different components involved in polyunsaturated fatty acid biosynthesis pathways, as well 
as adaptive defense mechanisms involved in the lipid-mediated modulation of inflammation, are also assessed. Our results show that the lipid 
profile in human frontal cortex is basically preserved through the adult life span to decay at advanced ages, which is accompanied by an 
adaptive proactive anti-inflammatory response possibly geared to ensuring cell survival and function.
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During the physiological aging process, human brain suffers from 
structural and physiological changes which become the substrate of 
age-associated cognitive decline (1–6). Among these, genomic and 
proteomic neuronal changes involved in energy metabolism, cytoskel-
eton, proteostasis, neurotransmission, O2/CO2 and heme metabolism, 
synaptic plasticity, vesicular transport, mitochondrial function, and 
stress-adaptive response have the greatest impact (2–4,6–10).
Human neurons are functional throughout the adult life span 
but the mechanisms that guarantee survival and preserve function, 
and protect them against harmful conditions, are poorly understood. 
Some recent evidence suggests adaptive response of stress resistance 
mechanisms based on the sustained expression of REST (6,7), and 
modifications in the expression of Akt and mTOR are substantial 
players (6) in maintaining neural cell survival and function.
Lipids have played a cardinal role in the evolution of the brain 
(11,12). Besides their quantitative importance (13), lipids of the 
nervous system show great structural and functional diversity 
(5,14). This diversity is linked to an intense dynamic cellular activity 
involved in lipid biosynthesis, remodeling, turnover, specific organi-
zation at the membrane level, and synthesis of lipid mediators which 
represents an energy investment of around 25% of total brain energy 
demand (15). All lipid classes are represented in the nervous system, 
which expresses the structural and functional complexity of the sys-
tem (14,16). Fatty acids are primary components in the structural 
diversity of lipids and they play a key role in the functional proper-
ties of the integrity of cell membranes, generation of lipid signaling 
mediators, and chemical reactivity of the acyl chains (5).
Changes in phospholipid composition are documented in human 
brain aging (17–22) and in several age-associated neurodegenera-
tive diseases such as Alzheimer disease (5). However, little is known 
about changes occurring throughout the life span.
The present study analyzes the membrane lipid fatty acid compo-
sitional profile in human frontal cortex area 8 in individuals ranging 
from 40 to 90 years old. Components of polyunsaturated fatty acid 
(PUFA) biosynthesis and adaptive defense mechanisms involved in 
lipid-mediated modulation of inflammation are also determined. The 
selection of frontal cortex is based on the fact that this region devel-
oped recently during primate evolution and is implicated in cognitive 
function (23,24). Our results demonstrate that the lipid profile in 
human frontal cortex is maintained throughout the adult life span 
to decay at advanced ages; this maintenance is accompanied by an 
adaptive proactive anti-inflammatory response geared to ensuring 
cell survival and function.
Methods
Chemicals
Unless otherwise specified, all reagents were from Sigma-Aldrich, 
and were of the highest purity available.
Human Samples
Brain samples were obtained from the Institute of Neuropathology 
Brain Bank, a branch of the HUB-ICO-IDIBELL Biobank, following 
the guidelines of Spanish legislation and the approval of the local 
ethics committee, and in accordance with recently published criteria 
for sample quality (25).
The neuropathological study was carried out in every case as 
previously described (26). At autopsy, one hemisphere was fixed in 
4% buffered formalin for about three weeks while the other hemi-
sphere was cut in coronal sections 1 cm thick; selected samples of the 
brain were dissected and kept in labeled plastic bags, immediately 
frozen on dry ice, and stored at −80°C until use. The neuropatho-
logical study was carried out on formalin-fixed, paraffin-embedded 
samples of 26 brain regions (6). Dewaxed sections, 5  µm thick, 
were stained with hematoxylin and eosin, and Kluver Barrera, or 
processed for immunohistochemistry to β-amyloid, phosphorylated 
tau, α-synuclein, ubiquitin, p62, TDP43, glial fibrillary protein, and 
microglia markers.
Selected cases showed no lesions on neuropathological exami-
nation, excepting neurofibrillary tangle pathology at stages I–II of 
Braak and β-amyloid Phase 1 of Thal in some old individuals, a fea-
ture which was consistent with normal aging. Cases with AD-related 
pathology, α-synuclein deposits, TDP43 proteinopathy, vascular 
diseases (other than mild small blood vessel disease), inflammatory 
and autoimmune diseases of the nervous system, and decompen-
sated systemic metabolic diseases (such as hepatic insufficiency, kid-
ney failure, and metabolic syndrome) and hypoxia were excluded. 
Following initial screening, the present series include 58 cases: 30 
males and 28 females, with an age ranging from 43 to 86 years. The 
postmortem delay ranged from 2 hours to 19 hours 30 minutes. 
Supplementary Table S1 summarizes cases examined in the present 
series. The grey matter of frozen samples from frontal cortex area 8 
was dissected and used for biochemical studies.
Fatty Acid Profile
Fatty acids from human frontal cortex homogenates were analyzed 
as methyl ester derivatives (FAMEs) by gas chromatography as previ-
ously described (27,28). Separation was performed with a DBWAX 
capillary column (30 m × 0.25  mm × 0.20 μm) in a GC System 
7890A with a Series Injector 7683B and a FID detector (Agilent 
Technologies, Barcelona, Spain). Identification of fatty acid methyl 
esters was made by comparison with authentic standards (Larodan 
Fine Chemicals, Malmö, Sweden). Results are expressed as mol%.
The following fatty acyl indices were also calculated: saturated 
fatty acids; unsaturated fatty acids; monounsaturated fatty acids; 
PUFA from n-3 and n-6 series (PUFAn-3 and PUFAn-6); and average 
chain length = ([Σ%Total14 × 14] + [Σ%Total16 × 16] + [Σ%Total18 
×  18] + [Σ%Total20 ×  20] + [Σ% Total22 ×  22] + [Σ% Total24 
× 24])/100. The density of double bonds in the membrane was calcu-
lated with the Double Bond Index = ([1 × Σmol% monoenoic] + [2 × 
Σmol% dienoic] + [3 × Σmol% trienoic] + [4 × Σmol% tetraenoic] + 
[5 × Σmol% pentaenoic] + [6 × Σmol% hexaenoic]). Membrane sus-
ceptibility to peroxidation was calculated with the Peroxidizability 
Index (PI) = ([0.025 × Σmol% monoenoic] + [1 × Σmol% dienoic] 
+ [2 × Σmol% trienoic] + (4 × Σmol% tetraenoic] + [6 × Σmol% 
pentaenoic] + [8 × Σmol% hexaenoic]).
Elongase and desaturase activities were estimated from specific 
product/substrate ratios: Δ9(n-7) = 16:1n-9/16:0; Δ9(n-9) = 18:1n-
9/18:0; Δ5 (n-6)  =  20:4n-6/20:3n-6; Δ6(n-3)1  =  18:4n-3/18:3n-3; 
Δ6(n-3)2  =  24:6n-3/24:5n-3; Elovl3(n-9)  =  20:1n-9/18:1n-9; 
Elovl6 = 18:0/16:0; Elovl1-3-7a = 20:0/18:0; Elovl1-3-7b = 22:0/20:0; 
Elovl1-3-7c = 24:0/22:0; Elovl 5(n-6) = 20:2n-6/18:2n-6; Elovl2-5 
(n-6)  =  22:4n-6/20:4n-6; Elovl 2-5(n-3)  =  22:5n-3/20:5n-3, and 
Elovl 2(n-3)= 24:5n-3/22:5n-3. Finally, peroxisomal β-oxidation was 
estimated according to the ratio 22:6n-3/24:6n-3.
Western Blotting
The protein expression related with (i) PUFA biosynthesis pathway, 
(ii) peroxisomal β-oxidation pathway, and (iii) neuroinflammatory 
markers was estimated using western blot analyses in samples from 
frontal cortex. Samples (50 mg) were homogenized in a buffer con-
taining 180 mM KCl, 5 mM 3-(N-morpholino)propanesulfonic acid, 
2 mM ethylenediaminetetraacetic acid, 1 mM diethylenetriamine-
pentaacetic acid, 1 µM butylated hydroxyltoluene, protease inhibitor 
mix (80-6501-23, Amersham Biosciences), and phosphatase inhibi-
tors (Na3VO4 1 mM, NaF 1 mM). After a brief centrifugation (1,000 
rpm at 4°C for 3 minutes) to pellet cellular debris, protein concentra-
tions were measured in the supernatants using the Bradford method 
(Bio-Rad Protein Assay 500-0006).
Proteins were separated with one-dimensional sodium dodecyl 
sulfate polyacrylamide gel electrophoresis, and for immunodetec-
tion proteins were transferred using a Mini Trans-Blot Transfer Cell 
(Bio Rad) to polyvinylidene difluoride membranes (Immobilon-P 
Millipore, Bedford, MA) as previously described (6). The primary 
specific antibodies used were: anti-FADS1 (Fatty Acid Desaturase 
1, ref. ab124363-Abcam, dilution: 1:300), anti-FADS2 (Fatty Acid 
Desaturase 2, ref. ab72189-Abcam, dilution: 1:500), anti-ELOVL2 
(Elongation of very-long-chain fatty acids 2, ref. NBP1-80719-Novus, 
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dilution: 1:300), anti-DBP-1 (D-Bifunctional protein, ref. NBP1-
85296-Novus, dilution: 1:300), anti-ACAA1 (Acetyl-CoA acyltrans-
ferase 1, ref. ab84635-Abcam, dilution: 1:1,000), anti-SCP2 (Sterol 
Carrier Protein 2, ref. ab82382-Abcam, dilution: 1:200), anti-5-LOX 
(Lipoxigenase-5, ref. ab169755-Abcam, dilution: 1:1,000), anti-
COX-2 (Cyclooxygenase-2, ref. ab52237-Abcam, dilution: 1:300), 
anti-NF-kBp65 (Nuclear Factor-ΚB-RelA, ref. ab32536-Abcam, 
dilution: 1:1,000), anti-15-LOX (Lipoxygenase-15, ref. ab119774-
Abcam, dilution: 1:500), anti-CYP450-2J2 (Cytochrome P450 2J2/
Epoxygenase, ref. ab139160-Abcam, dilution: 1:500), anti-Actin 
(Sigma-a5441, dilution 1:5,000), and anti-Tubulin (ab7291-Abcam, 
dilution 1:5,000).
Each membrane was washed and incubated with the appropri-
ate secondary antibodies: ECL Anti-mouse IgG, horseradish peroxi-
dase linked whole antibody-NA93IV GE Healthcare (1:30,000) and 
ImmunoPure Goat Anti-rabbit IgG peroxidase conjugated-31460 
Pierce Biotechnology (1:100,000) as previously described (6).
Bands were visualized using an enhanced chemiluminescence 
HRP substrate (Millipore, MA). Signal quantification and recording 
was performed with ChemiDoc equipment (Bio-Rad Laboratories, 
Inc., Barcelona, Spain). The amounts of the determined proteins 
were specifically calculated from the ratio of their densitometry val-
ues in reference to the densitometry values of actin or tubulin.
RNA Purification, Retrotranscription Reaction, and 
TaqMan PCR
The purification of RNA from human frontal cortex (n = 3–4 sam-
ples per decade) was carried out with RNeasy Lipid Tissue Mini Kit 
(Qiagen, Hilden, Germany) following the protocol provided by the 
manufacturer, following DNase digest to avoid extraction and later 
amplification of genomic DNA. Quality of isolated RNA was first 
measured with Bioanalyzer Assay (Agilent, Santa Clara, CA). The 
concentration of each sample was obtained from A260 measure-
ments with Nanodrop 2000 (Thermo Scientific, Wilmington, DE). 
RNA integrity (RIN) was tested using the Agilent 2100 BioAnalyzer 
(Agilent Technologies, Palo Alto, CA). RIN values were higher than 
6 for all samples used.
The retrotranscriptase reaction was carried out using a High-
Capacity cDNA Archive kit (Applied Biosystems, Foster City, CA) 
following the protocol provided by the supplier. Parallel reactions 
for an RNA sample were run in the absence of MultiScribe Reverse 
Transcriptase to assess the degree of contaminating genomic DNA.
TaqMan quantitative RT-PCR assays for each gene were per-
formed in triplicate on cDNA samples obtained from the retrotran-
scription reaction using the ABI Prism 7900 Sequence Detection 
system (Applied Biosystems, Life Technologies, Waltham, MA). For 
each 10 μL TaqMan reaction, 4.5 μL cDNA was mixed with 0.5 
μL 20× TaqMan Gene Expression Assays and 5 μL of 2× TaqMan 
Universal PCR Master Mix (Applied Biosystems). The reactions 
were carried out using the following parameters: 50°C for 2 min-
utes, 95°C for 10 minutes, 40 cycles of 95°C for 15 seconds and 
60°C for 1 minute. Finally, all TaqMan PCR data were captured 
using the Sequence Detection Software (SDS version 1.9; Applied 
Biosystems). The identification numbers and names of all TaqMan 
probes used are shown in Supplementary Table S2. Samples were 
analyzed with the double-delta cycle threshold (ΔΔCT) method. The 
ΔCT values represent normalized target gene levels with respect to 
the internal control (ACTB). The ΔΔCT values were calculated as 
the ΔCT of each test sample minus the mean ΔCT of the calibrator 
samples for each target gene. The fold change was determined using 
the equation 2(−ΔΔCT).
Statistics
To model the relationships between frontal cortex age and fatty acid 
indexes, both generalized additive model (GAM) and Jointpoint 
regression were used as previously described (6). These two analyses 
were made using the R statistical package 2.10 in conjunction with 
the “mgcv” and “segmented” library.
Comparisons between groups were made with one-way analysis 
of variance. The minimum level of statistical significance was set at 
p less than .05 in all the analyses. These statistical analyses were 
performed using the SPSS software (SPSS, Chicago, IL).
Results
In the present study, we evaluated the temporal trajectories over the 
adult life span in frontal cortex grey matter fatty acid composition 
using gas chromatography in subjects aged 40–90 years (n  = 58). 
Our prediction was that increasing age would be associated with 
significant progressive and specific changes in the fatty acid profile 
and fatty acid indexes. Age-related changes in fatty acid indexes are 
Figure  1. Relationship between age and different fatty acid indexes in 
human frontal cortex. Graphics show the trend for each variable with age, 
analyzed by generalized additive model (GAM). Significance of the GAM 
analysis is: for saturated fatty acids (SFA), R2(adj) = 0.112, p < .01, Deviance 
explained  =  1.34%; for unsaturated fatty acids (UFA), R2(adj)  =  0.112, p < 
.01, Deviance explained = 1.34%; for Polyunsaturated Fatty Acids series n-6 
(PUFAn-6), R2 (adj) = 0.116, p < .01, Deviance explained = 13.8%; for Double 
Bond Index (DBI), R2(adj)  =  0.063, p < .05, Deviance explained  =  8.39%; 
and for Average Chain Length (ACL), R2(adj)  =  0.146, p < .01, Deviance 
explained = 16.9%.
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shown in Figure 1. Our results demonstrate the existence of a signifi-
cant relationship between frontal cortex fatty acid indexes and age 
analyzed by generalized additive model. In particular, this relation-
ship shows an increase with age in the saturated fatty acid content 
(R2[adj] = 0.112, p < .01, Deviance explained: 1.34%), and decrease 
with age in the unsaturated fatty acid content (R2[adj]  =  0.112, 
p < .01, Deviance explained: 1.34%), basically due to the decrease 
with age in the PUFAn-6 content (R2[adj] = 0.116, p < .01, Deviance 
explained: 13.8%) which, in turn, leads to a decrease with age in the 
Double Bond Index (R2[adj] = 0.063, p < .05, Deviance explained: 
8.39%). A decrease with age in the average chain length was also 
observed (R2[adj] = 0.146, p < .01, Deviance explained = 16.9%). 
In contrast, no changes associated with age in the monounsaturated 
fatty acid content (R2[adj] = 0.041, p =  .287, Deviance explained: 
7.85%), PUFA content (R2[adj]  =  0.027, p  =  .0861, Deviance 
explained: 7.89%), PUFAn-3 content (R2[adj] = −0.0269, p = .375, 
Deviance explained: 0.729%), or PI (R2[adj]  =  0.0136, p  =  .153, 
Deviance explained: 6.16%) were observed (data not shown). 
Potential interference of the variables of gender and postmortem 
time in the temporal trajectories of the different fatty acid indexes 
was ruled out after applying the corresponding generalized additive 
model analysis (see Supplementary Figure S1).
To shed light upon a possible juncture at which brain aging begins, 
we applied a jointpoint regression model to determine the break-
point where the temporal trajectories for fatty acid indexes showed 
a significant tipping point followed by a more pronounced increase/
decrease in fatty acid indexes. Our analysis indicates that the break-
point is at 50 years old for average chain length (52.16 ± 3.60 years 
old, R2[adj] = 0.153), at 60 years old for saturated fatty acids and 
unsaturated fatty acids (59.57 ± 7.58 years old, R2[adj] = 0.103, for 
both), and at 75  years old for PUFAn-6 (75.90  ±  4.53  years old, 
R2[adj] = 0.128), with no significant breakpoints for the rest of the 
fatty acid indexes.
Table 1 shows changes in frontal cortex of individual fatty acids 
with age, and with subjects grouped by decades. Of particular rel-
evance is the significant increase in the saturated fatty acid palmitic 
acid (16:0) content in the decade following age 70, and the sig-
nificant decay in the polyunsaturated fatty acids arachidonic acid 
(AA, 20:4n-6), adrenic acid (22:4n-6), docosapentaenoic acid (DPA, 
22:5n-6), and docosahexaenoic acid (DHA, 22:6n-3) in the decade 
following age 80, a decade in which more significant changes are 
verified, in contrast to the previous decades during which the fatty 
acid profile is sustained without significant changes. The observed 
changes at advanced ages could potentially be ascribed to defects in 
the PUFA biosynthesis pathways in accordance with the ratios esti-
mating desaturase and elongase activity, which suggests an altera-
tion in delta-6-desaturase (FADS2) and ELOVL2 activity, as well as 
in peroxisomal β-oxidation (Supplementary Tables S3, S4, and S5).
Because the most significant changes observed in the fatty acid 
profile are found at advanced ages and affect polyunsaturated fatty 
acids, we investigated protein expression related to PUFA biosynthe-
sis. In particular, we focused our attention on the enzymes participat-
ing in PUFA biosynthesis FADS1, FADS2, and ELOVL2, as well as 
the enzymes DBP-1, ACAA1, and SCP2, belonging to peroxisomal 
β-oxidation. Our results showed a significant decrease with age in 
the content of FADS2 and ELOVL2, with this trajectory especially 
evident at advanced ages (Figure 2A). These changes are likely post-
transcriptional because no changes were observed in the mRNA con-
tent with age (Figure 2B). In contrast, the expression of FADS1 and 
proteins of peroxisomal β-oxidation did not show any differences 
with age (Figure 2A and C).
Table 1. Membrane Lipid Fatty Acid Compositional Profile of the Human Frontal Cortex in Individuals Ranging from 40 to 90 Years Old
Fatty Acid
Decade 40–49 (years), 
n = 6
Decade 50–59 (years), 
n = 10
Decade 60–69 (years), 
n = 9
Decade 70–79 (years)  
n = 22
Decade 80–89 (years)  
n = 11
14:0 1.48 ± 0.17 1.21 ± 0.07 1.53 ± 0.13b* 1.19 ± 0.07a*,c** 1.31 ± 0.06
16:0 21.19 ± 0.66 20.27 ± 0.74 20.15 ± 0.85 25.32 ± 0.65a***,b***,c*** 24.17 ± 0.71a**,b***,c**
16:1n-7 1.47 ± 0.13 1.45 ± 0.10 1.85 ± 0.17a*,b* 1.47 ± 0.08 a*,b*,c*** 1.24 ± 0.08 c***
18:0 21.43 ± 0.97 21.27 ± 0.61 20.30 ± 1.47 20.11 ± 0.59 22.45 ± 1.08d*
18:1n-9 26.56 ± 1.46 26.35 ± 1.04 27.82 ± 1.30 23.87 ± 0.66c** 27.46 ± 1.25d**
18:2n-6 1.11 ± 0.10 1.16 ± 0.10 1.21 ± 0.13 1.16 ± 0.06 1.04 ± 0.07
18:3n-3 0.20 ± 0.05 0.19 ± 0.04 0.32 ± 0.15 0.25 ± 0.02 0.25 ± 0.04
18:4n-3 0.37 ± 0.20 0.20 ± 0.05 0.44 ± 0.24 0.36 ± 0.05 0.41 ± 0.06
20:0 0.37 ± 0.07 0.74 ± 0.42 0.42 ± 0.12 0.49 ± 0.03 0.46 ± 0.04
20:1n-9 1.36 ± 0.17 1.41 ± 0.17 1.81 ± 0.18a* 1.13 ± 0.07c*** 1.43 ± 0.19
20:2n-6 0.43 ± 0.12 0.31 ± 0.05 0.51 ± 0.19 0.36 ± 0.02 0.38 ± 0.02
20:3n-6 1.18 ± 0.26 1.04 ± 0.05 1.54 ± 0.46 1.21 ± 0.08 1.09 ± 0.15
20:4n-6 6.92 ± 0.43 6.73 ± 0.38 6.26 ± 0.32 6.55 ± 0.30 5.37 ± 0.32a**,b**,d**
20:5n-3 0.33 ± 0.12 0.25 ± 0.04 0.38 ± 0.18 0.34 ± 0.04 0.51 ± 0.27
22:0 0.38 ± 0.10 0.73 ± 0.43 0.46 ± 0.13 0.42 ± 0.02 0.40 ± 0.04
22:4n-6 4.27 ± 0.33 4.64 ± 0.20 4.40 ± 0.31 4.26 ± 0.23 3.51 ± 0.26b**,c*,d*
22:5n-6 1.19 ± 0.24 1.08 ± 0.12 1.16 ± 0.30 0.98 ± 0.07 0.72 ± 0.08a*
22:5n-3 0.58 ± 0.18 0.53 ± 0.05 0.60 ± 0.22 0.61 ± 0.04 0.44 ± 0.04
22:6n-3 8.07 ± 0.95 9.15 ± 0.67 7.42 ± 0.60 9.28 ± 0.63 6.40 ± 0.67b*,d**
24:0 0.59 ± 0.09 0.78 ± 0.18 0.71 ± 0.14 0.65 ± 0.05 0.69 ± 0.09
24:5n-3 0.29 ± 0.06 0.28 ± 0.02 0.40 ± 0.09b* 0.15 ± 0.01a**,b**,c*** 0.14 ± 0.02a**,b**,c***
24:6n-3 0.24 ± 0.05 0.24 ± 0.04 0.31 ± 0.08 0.15 ± 0.02c** 0.11 ± 0.02a*,b*,c***
Note: Values are means ± SEM from 6 to 22 different cases and are expressed as mol%.
aSignificantly different from 40 to 49 group. bSignificantly different from 50 to 59 group. cSignificantly different from 60 to 69 group. dSignificantly different 
from 70 to 79 group.
*p < .05, **p < .01, ***p < .001.
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Our findings suggest that the membrane lipid fatty acid profile in 
human prefrontal cortex is sustained over the adult life span only to 
decay at advanced age, and that this decay could be ascribed to par-
ticular defects in PUFA biosynthesis. However, other mechanisms may 
also be considered. Thus, the decrease in particular polyunsaturated 
fatty acids observed at advanced ages might be associated with an 
increase in the consumption of them to generate lipid signaling medi-
ator or second messengers to ensure neuronal survival and function. 
To this end, we investigated the content of pro-inflammatory factors 
lipoxigenase-5 (5-LOX), cyclooxygenase-2 (COX2), and NF-kB, as 
well as anti-inflammatory factors lipoxygenase-15 (15-LOX) and 
cytochrome P450 epoxygenase (CYP450 2J2). Our results showed a 
significant progressive increase in the protein expression of CYP450 
2J2 with age (Figure  3B) which was consistent with the increase 
(albeit without significant) in its mRNA content (Figure 3C), as well 
as sustained protein content of 15-LOX despite decreased mRNA 
levels. These showed a significant decline in the decades following 
age 70 probably due to an increased translation rate (Figure 3B and 
C). In contrast, the expression of none of the proinflammatory fac-
tors showed any difference with age (Figure 3A).
Discussion
The physiological aging process favors the induction of changes 
at all levels of the biological organization which are balanced by 
homeostatic adaptive response mechanisms geared to preserving 
the composition and function within physiological limits (29). Cell 
membranes are not an exception; consequently, the longer the opti-
mal membrane lipid composition is maintained, the better cell sur-
vival and function.
The studies by Burger & Seidel (30) and Rouser & Yamamoto 
(31) were the first evidence that the lipid profile of the human brain 
changes with aging. Burger & Seidel (30) found that the amount of 
total lipids increased during the first two decades of life and then 
began to decrease. Rouser & Yamamoto (31) also demonstrated a 
curvilinear regression of human brain lipid levels with age; however, 
as pointed out by Ledesma et  al. (32), in both studies the use of 
whole brains to analyze lipids resulted in variations in lipid content 
that precluded an evaluation of separate changes in the grey and 
white matter.
Later on, several studies of different areas of human brain con-
firmed the occurrence of age-related lipid changes. Overall, changes 
are in line with the assumption of the progressive and deleterious 
character of the aging process, as the contents of most lipids in the 
human brain decrease after the age of 50. Thus, phosphatidylino-
sitol (PI), phosphatidylethanolamine (PE), and phosphatidylcholine 
(PC) brain levels decrease very slowly with age, with less than 10% 
loss in the period between the ages of 40 and 100 years old (33). 
Another study described 10%–20% loss of phospholipids in differ-
ent brain regions (gray matter, white matter, nucleus caudate, hip-
pocampus, pons, cerebellum, medulla oblongata) only in individuals 
aged from 89 to 92 when compared with individuals aged from 33 
to 36, whereas phospholipid composition remained unchanged (19). 
Phospholipid decrease starts slowly at the age of 20 and becomes 
Figure 2. Representative immunoblots showing the relative levels of protein involved in PUFA biosynthesis (A) and peroxisomal β-oxidation (C). The mRNA 
relative expression of FADS1, FADS2, and ELOVL2 is also illustrated (B). Values are expressed as mean ± SEM from five different frontal cortex human samples 
normalized for tubulin or actin protein levels as a tissue marker. aSignificantly different from 40 to 49 group, bsignificantly different from 50 to 59 group, 
csignificantly different from 60 to 69 group, dsignificantly different from 70 to 79 group. *p < .05, **p < .01.
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more pronounced by the age of 80, with no significant differences 
between male and female (34,35). More recent studies focused on 
the mitochondrial and microsomal lipidome of frontal cortex and 
hippocampus of subjects from 20 to 100 years old (21,22), showing 
that minor fractions of phospholipids containing adrenic and ara-
chidonic acid specifically decrease along adult life in both regions, 
whereas particular phospholipids containing docosahexanoic acid 
increase during the same period. These data, however, must be 
approached with care because fractionation methods from frozen 
human tissue do not prevent contamination of membrane fractions. 
Additionally, no changes are observed in the mole percentage of lipid 
classes and fatty acid composition of lipid rafts from normal human 
frontal cortex throughout the human life span (24–85 years) (36).
Only two recent studies have focused on the human frontal 
cortex fatty acid profile, analyzing subjects aged 20–80-year old 
(37,38). Our results, together with the findings of these two previous 
studies, suggest the following three basic points: (i) maintenance or 
minor changes with age in the saturated and monounsaturated fatty 
acid content, (ii) decrease in the polyunsaturated fatty acid series 
n-6 content with age, particularly affecting arachidonic (20:4n-6) 
and adrenic acid (22:4n-6), and (iii) maintenance of docosahexae-
noic acid (22:6n-3) content during aging with eventual reduction at 
a very advanced age.
Maintenance of saturated-monounsaturated fatty acid and 
the highly polyunsaturated fatty acid DHA content with aging 
can be interpreted as a sign of stability. Saturated, monounsatu-
rated, and docosahexaenoic acid are key fatty acids determining 
the geometric properties of lipids, and affecting functional prop-
erties such as exocytosis and membrane domain formation (14). 
However, changes in the average chain length and double bond 
index with aging can influence the geometric properties of lipids 
and functional properties. Yet the impact of these changes in 
neural cell membrane physiology during aging remains to be 
explored.
In contrast to these observations, PUFAn-6, and particularly the 
20:4n-6 and 22:4n-6 fatty acid content, has an effect as a substrate 
for lipid mediators. Thus, in addition to the defects in PUFA bio-
synthesis pathway observed in our work, the decrease in these fatty 
acids may possibly be ascribed to increased consumption by enzymes 
involved in anti-inflammatory pathways which synthesize a diversity 
of compounds with neuroprotective properties to ensure cell survival 
and functioning during normal aging.
The present observations may have implications in neuronal 
physiology and, by extension, brain function. Thus, the described 
changes in PUFA content (particularly 20:4n6 and 22:6n3), average 
chain length, and double bond index—the major factors determin-
ing the geometric properties of membrane lipids (14)—have key 
consequences on functional properties of neurons such as synaptic 
vesicle exocytosis, ion channel regulation, membrane domain for-
mation, G-protein signaling or survival pathways (14,39), mecha-
nisms underlying memory and learning processes and affected 
during aging (32).
Available evidence suggests that an adequate dietary intake of 
PUFAs (n3 and/or n6) could prevent or slow down cognitive decline 
Figure 3. Representative immunoblots showing the relative levels of protein involved in proinflammatory (A) and anti-inflammatory pathways (B). The mRNA 
relative expression for the anti-inflammatory factors lipoxygensase-15 and cytochrome P450 epoxygenase is also illustrated (C). Values are expressed as mean 
± SEM from five different human brain samples normalized for tubulin or actin protein levels. asignificantly different from 40 to 49 group, bsignificantly different 
from 50 to 59 group, csignificantly different from 60 to 69 group, dsignificantly different from 70 to 79 group. *p < .05, ***p < .001.
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and attenuate the physiological changes of the brain that are associ-
ated with aging (40–45). However, the outcomes from these stud-
ies are not conclusive, and more experimental data are needed to 
determine PUFA’s dose, type, duration, targets of action in brain, 
impacted cognitive traits, involved mechanisms, or responsive popu-
lations. In a similar way, another nutritional intervention such as 
caloric restriction seems to improve synaptic plasticity and activa-
tion of neuroprotective pathways in the brain (at least in animal 
studies) but again fail to offer conclusive outcomes when applied to 
human studies, basically due to the scarcity of works in this research 
line (46–48).
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